MetaCap

Novavax Inc. (NVAX)

NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

7.47-0.25 (-3.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NVAX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.52
52-week range
6.36 – 13.39
Day range
7.43 – 7.98
Volume / Avg
4.73M / 6.67M
Beta
—

52-week range

$6.36$13.39

NVAX stock today

Shares of Novavax (NVAX) finished lower on Nov 20 at $7.47, a drop of 3.24% or $0.25 per share, versus the S&P 500's 3.70% decline. Shares are 44.2% below their 52-week high of $13.39, set on Oct 5, 2026 and 17.5% above the 52-week low of $6.36, near the bottom of the past year's range. NVAX is up 11.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 15.5%.

Novavax has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Novavax

Company profile

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. John Charles Jacobs M.B.A.
Headquarters
Gaithersburg, MD
Employees
749

Financial highlights

Full financials

In fiscal 2025, Novavax generated $1.12 billion in revenue, up 64.7% from fiscal 2024. Net income was $440.3 million, for a net margin of 39.2% versus a median of -55.4% in the prior 5 years. Gross margin was 93.5% (up from 70.3%) and operating margin 40.3%.

Novavax annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.12B$682.16M$983.71M$1.98B$1.15B
Growth+64.69%-30.65%-50.36%+72.89%+141.02%
Net income$440.30M$-187.50M$-545.06M$-657.94M$-1.74B
EPS (diluted)$2.58$-1.23$-5.41$-8.42$-23.44

Analyst forecast

Forecast

Consensus (9 analysts)

buy

Avg. price target

$14.11+88.89%

  • Strong buy 0
  • Buy 5
  • Hold 1
  • Sell 1
  • Strong sell 2

Target range

Low $7.00High $25.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.19 vs $-0.37
Surprise
+48.65%

NVAX news

All NVAX news

Novavax peers

Health Care sector
NVAX peer companies
CompanyPrice% ChgMarket capCompare
TSHATaysha Gene Therapies Inc.3.72-1.33%$1.21Bvs NVAX
VORVor Biopharma Inc.19.19+3.62%$1.18Bvs NVAX
IMCRImmunocore Holdings plc ADR26.41-0.83%$1.36Bvs NVAX
MESOMesoblast Limited ADR10.89-2.59%$1.41Bvs NVAX
INBXInhibrx Biosciences Inc.68.97-7.21%$1.02Bvs NVAX
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs NVAX
ALVOAlvotech4.12-3.96%$1.47Bvs NVAX
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs NVAX

Indexes, lists and sector

Novavax stock FAQ

What is Novavax's stock price today?

NVAX last traded at $7.47 as of Nov 20, 4:00 PM EST, down 3.24% on the day. Prices are delayed at least 15 minutes.

Does Novavax pay a dividend?

No. Novavax does not currently pay a regular cash dividend.

Who is Novavax's CEO?

Mr. John Charles Jacobs M.B.A. is the chief executive officer of Novavax Inc., which has about 749 employees.

Has NVAX ever split its stock?

Yes. The most recent NVAX stock split was a 1-for-20 split on May 10, 2019.

What is the NVAX 52-week high?

The 52-week high for NVAX is $13.39 and the 52-week low is $6.36. The stock is currently 44.2% below its high.

Compare NVAX